121MO Anti-IL-8 (BMS-986253) in combination with nivolumab (NIVO) plus ipilimumab (IPI) in patients (pts) with advanced melanoma: Final analysis from the randomized part 2 of the phase I/II CA027-002 study

2 confirmed CR's, was observed at the 80 mg dose.A total of 34 participants had at least 6 months follow up; median PFS in this subset was 7.7 months (95% CI 4.9,11.0).Preliminary translational analyses indicate that serum CXCL13 increase may be associated with responses. Conclusions:The combination of inupadenant and carboplatin-pemetrexed had a manageable safety profile and preliminary clinical activity in advanced NSCLC post ICI therapy.The study is ongoing and updated safety, efficacy, and translational data will be presented.

Authors

Institutions

Publication Details

Journal
Immuno-Oncology Technology
Published
2024-12-01
DOI
https://doi.org/10.1016/j.iotech.2024.100750
Citations
1
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.28

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

121MO Anti-IL-8 (BMS-986253) in combination with nivolumab (NIVO) plus ipilimumab (IPI) in patients (pts) with advanced melanoma: Final analysis from the randomized part 2 of the phase I/II CA027-002 study

Víctor Moreno, P.A. Ascierto, Manoj Kumar, Matteo Simonelli et al.
1 citations
Immuno-Oncology Technology
Cancer Immunotherapy and Biomarkers
0.28
article

121MO Anti-IL-8 (BMS-986253) in combination with nivolumab (NIVO) plus ipilimumab (IPI) in patients (pts) with advanced melanoma: Final analysis from the randomized part 2 of the phase I/II CA027-002 study

Víctor Moreno, P.A. Ascierto, Manoj Kumar, Matteo Simonelli, A.M. Haydon, E. Calvo, J.J. Grob, Ignacio Melero, C. Gebhardt, Xu Zhu, G.V. Long, D. Chakraborty, J. Walker, Gaelle Quereux, M.O. Butler
article en
1 citations

Abstract

2 confirmed CR's, was observed at the 80 mg dose.A total of 34 participants had at least 6 months follow up; median PFS in this subset was 7.7 months (95% CI 4.9,11.0).Preliminary translational analyses indicate that serum CXCL13 increase may be associated with responses. Conclusions:The combination of inupadenant and carboplatin-pemetrexed had a manageable safety profile and preliminary clinical activity in advanced NSCLC post ICI therapy.The study is ongoing and updated safety, efficacy, and translational data will be presented.

Immuno-Oncology TechnologyVol. 24
Humanitas University (IT), Bristol-Myers Squibb (Germany) (DE), Universität Hamburg (DE), Royal North Shore Hospital (AU), The Alfred Hospital (AU), Princess Margaret Cancer Centre (CA), Assistance Publique Hôpitaux de Marseille (FR), University Medical Center Hamburg-Eppendorf (DE), Melanoma Institute Australia (AU), Hospital Universitario Fundación Jiménez Díaz (ES), Bristol-Myers Squibb (Sweden) (SE), Clinica Universidad de Navarra (ES), Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT), Hôpital de la Timone (FR), IRCCS Humanitas Research Hospital (IT), Nantes Université (FR)
European Society for Medical Oncology, Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung, PharmaMar, Genentech
Good health and well-being
Openalex Percentile: Top 33%
Cancer Immunotherapy and Biomarkers
0.28
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.